1
|
Meltsner SG, Rodrigues A, Materin MA, Kirsch DG, Craciunescu O. Transitioning from a COMS-based plaque brachytherapy program to using eye physics plaques and plaque simulator treatment planning system: A single institutional experience. J Appl Clin Med Phys 2023; 24:e13902. [PMID: 36637797 PMCID: PMC10161060 DOI: 10.1002/acm2.13902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2022] [Revised: 11/08/2022] [Accepted: 12/15/2022] [Indexed: 01/14/2023] Open
Abstract
The aim of this work is to describe the implementation and commissioning of a plaque brachytherapy program using Eye Physics eye plaques and Plaque Simulator treatment planning system based on the experience of one institution with an established COMS-based plaque program. Although commissioning recommendations are available in official task groups publications such as TG-129 and TG-221, we found that there was a lack of published experiences with the specific details of such a transition and the practical application of the commissioning guidelines. The specific issues addressed in this paper include discussing the lack of FDA approval of the Eye Physics plaques and Plaque Simulator treatment planning system, the commissioning of the plaques and treatment planning system including considerations of the heterogeneity corrected calculations, and the implementation of a second check using an FDA-approved treatment planning system. We have also discussed the use of rental plaques, the analysis of plans using dose histograms, and the development of a quality management program. By sharing our experiences with the commissioning of this program this document will assist other institutions with the same task and act as a supplement to the recommendations in the recently published TG-221.
Collapse
Affiliation(s)
- Sheridan G Meltsner
- Department of Radiation Oncology, Duke University, Durham, North Carolina, USA
| | - Anna Rodrigues
- Department of Radiation Oncology, Duke University, Durham, North Carolina, USA
| | - Miguel A Materin
- Departments of Ophthalmology, Duke University, Durham, North Carolina, USA
| | - David G Kirsch
- Department of Radiation Oncology, Duke University, Durham, North Carolina, USA
| | - Oana Craciunescu
- Department of Radiation Oncology, Duke University, Durham, North Carolina, USA
| |
Collapse
|
2
|
Sloboda RS, Morrison H, Cawston-Grant B, Menon GV. A brief look at model-based dose calculation principles, practicalities, and promise. J Contemp Brachytherapy 2017; 9:79-88. [PMID: 28344608 PMCID: PMC5346608 DOI: 10.5114/jcb.2017.65849] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Accepted: 01/07/2017] [Indexed: 12/22/2022] Open
Abstract
Model-based dose calculation algorithms (MBDCAs) have recently emerged as potential successors to the highly practical, but sometimes inaccurate TG-43 formalism for brachytherapy treatment planning. So named for their capacity to more accurately calculate dose deposition in a patient using information from medical images, these approaches to solve the linear Boltzmann radiation transport equation include point kernel superposition, the discrete ordinates method, and Monte Carlo simulation. In this overview, we describe three MBDCAs that are commercially available at the present time, and identify guidance from professional societies and the broader peer-reviewed literature intended to facilitate their safe and appropriate use. We also highlight several important considerations to keep in mind when introducing an MBDCA into clinical practice, and look briefly at early applications reported in the literature and selected from our own ongoing work. The enhanced dose calculation accuracy offered by a MBDCA comes at the additional cost of modelling the geometry and material composition of the patient in treatment position (as determined from imaging), and the treatment applicator (as characterized by the vendor). The adequacy of these inputs and of the radiation source model, which needs to be assessed for each treatment site, treatment technique, and radiation source type, determines the accuracy of the resultant dose calculations. Although new challenges associated with their familiarization, commissioning, clinical implementation, and quality assurance exist, MBDCAs clearly afford an opportunity to improve brachytherapy practice, particularly for low-energy sources.
Collapse
Affiliation(s)
- Ron S. Sloboda
- Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton
- Department of Medical Physics, Cross Cancer Institute, Alberta Health Services, Edmonton, Alberta, Canada
| | - Hali Morrison
- Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton
- Department of Medical Physics, Cross Cancer Institute, Alberta Health Services, Edmonton, Alberta, Canada
| | - Brie Cawston-Grant
- Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton
- Department of Medical Physics, Cross Cancer Institute, Alberta Health Services, Edmonton, Alberta, Canada
| | - Geetha V. Menon
- Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Edmonton
- Department of Medical Physics, Cross Cancer Institute, Alberta Health Services, Edmonton, Alberta, Canada
| |
Collapse
|
3
|
Morrison H, Menon G, Larocque MP, Jans HS, Weis E, Sloboda RS. Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy. Med Phys 2016; 43:4891. [DOI: 10.1118/1.4959540] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
|
4
|
Chiu-Tsao ST, Astrahan MA, Finger PT, Followill DS, Meigooni AS, Melhus CS, Mourtada F, Napolitano ME, Nath R, Rivard MJ, Rogers DWO, Thomson RM. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS. Med Phys 2012; 39:6161-84. [PMID: 23039655 DOI: 10.1118/1.4749933] [Citation(s) in RCA: 146] [Impact Index Per Article: 12.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Dosimetry of eye plaques for ocular tumors presents unique challenges in brachytherapy. The challenges in accurate dosimetry are in part related to the steep dose gradient in the tumor and critical structures that are within millimeters of radioactive sources. In most clinical applications, calculations of dose distributions around eye plaques assume a homogenous water medium and full scatter conditions. Recent Monte Carlo (MC)-based eye-plaque dosimetry simulations have demonstrated that the perturbation effects of heterogeneous materials in eye plaques, including the gold-alloy backing and Silastic insert, can be calculated with reasonable accuracy. Even additional levels of complexity introduced through the use of gold foil "seed-guides" and custom-designed plaques can be calculated accurately using modern MC techniques. Simulations accounting for the aforementioned complexities indicate dose discrepancies exceeding a factor of ten to selected critical structures compared to conventional dose calculations. Task Group 129 was formed to review the literature; re-examine the current dosimetry calculation formalism; and make recommendations for eye-plaque dosimetry, including evaluation of brachytherapy source dosimetry parameters and heterogeneity correction factors. A literature review identified modern assessments of dose calculations for Collaborative Ocular Melanoma Study (COMS) design plaques, including MC analyses and an intercomparison of treatment planning systems (TPS) detailing differences between homogeneous and heterogeneous plaque calculations using the American Association of Physicists in Medicine (AAPM) TG-43U1 brachytherapy dosimetry formalism and MC techniques. This review identified that a commonly used prescription dose of 85 Gy at 5 mm depth in homogeneous medium delivers about 75 Gy and 69 Gy at the same 5 mm depth for specific (125)I and (103)Pd sources, respectively, when accounting for COMS plaque heterogeneities. Thus, the adoption of heterogeneous dose calculation methods in clinical practice would result in dose differences >10% and warrant a careful evaluation of the corresponding changes in prescription doses. Doses to normal ocular structures vary with choice of radionuclide, plaque location, and prescription depth, such that further dosimetric evaluations of the adoption of MC-based dosimetry methods are needed. The AAPM and American Brachytherapy Society (ABS) recommend that clinical medical physicists should make concurrent estimates of heterogeneity-corrected delivered dose using the information in this report's tables to prepare for brachytherapy TPS that can account for material heterogeneities and for a transition to heterogeneity-corrected prescriptive goals. It is recommended that brachytherapy TPS vendors include material heterogeneity corrections in their systems and take steps to integrate planned plaque localization and image guidance. In the interim, before the availability of commercial MC-based brachytherapy TPS, it is recommended that clinical medical physicists use the line-source approximation in homogeneous water medium and the 2D AAPM TG-43U1 dosimetry formalism and brachytherapy source dosimetry parameter datasets for treatment planning calculations. Furthermore, this report includes quality management program recommendations for eye-plaque brachytherapy.
Collapse
|
5
|
Melhus CS. Improved Eye Plaque Brachytherapy Dosimetry Using Monte Carlo Methods. NUCL TECHNOL 2011. [DOI: 10.13182/nt11-a12266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Christopher S. Melhus
- Tufts Medical Center, Tufts Medical Center, Box 246 800 Washington Street, Boston, Massachusetts 02111
| |
Collapse
|
6
|
Saidi P, Sadeghi M, Shirazi A, Tenreiro C. ROPES eye plaque brachytherapy dosimetry for two models of 103Pd seeds. AUSTRALASIAN PHYSICAL & ENGINEERING SCIENCES IN MEDICINE 2011; 34:223-31. [DOI: 10.1007/s13246-011-0069-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2010] [Accepted: 03/18/2011] [Indexed: 10/18/2022]
|
7
|
Thomson RM, Taylor REP, Rogers DWO. Monte Carlo dosimetry for I125 and Pd103 eye plaque brachytherapy. Med Phys 2008; 35:5530-5543. [DOI: 10.1118/1.3002412] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2008] [Revised: 09/22/2008] [Accepted: 09/22/2008] [Indexed: 11/07/2022] Open
|
8
|
Melhus CS, Rivard MJ. COMS eye plaque brachytherapy dosimetry simulations for P103d, I125, and C131s. Med Phys 2008; 35:3364-3371. [DOI: 10.1118/1.2940604] [Citation(s) in RCA: 56] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2007] [Revised: 05/20/2008] [Accepted: 05/20/2008] [Indexed: 11/07/2022] Open
|
9
|
Murphree AL, Samuel MA, Harbour JW, Mansfield NC. Retinoblastoma. Retina 2006. [DOI: 10.1016/b978-0-323-02598-0.50028-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Astrahan MA, Szechter A, Finger PT. Design and dosimetric considerations of a modified COMS plaque: The reusable “seed-guide” insert. Med Phys 2005; 32:2706-16. [PMID: 16193802 DOI: 10.1118/1.1993828] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
The Collaborative Ocular Melanoma Study (COMS) developed a standardized set of eye plaques that consist of a 0.5 mm thick bowl-like gold alloy backing with a cylindrical collimating lip. A Silastic seed carrier into which 125I seeds are loaded was designed to fit within the backing. The carrier provides a standardized seed pattern and functions to offset the seeds by 1.0 mm from the concave (front) surface of the carrier. These Silastic carriers have been found to be difficult to load, preclude flash sterilization, and are a source of dosimetric uncertainty because the effective atomic number of Silastic is significantly higher than that of water. The main dosimetric effect of the Silastic carrier is a dose-reduction (compared to homogeneous water) of approximately 10%-15% for 125I radiation. The dose reduction is expected to be even greater for 103Pd radiation. In an attempt to improve upon, yet retain as much of the familiar COMS design as possible, we have developed a thin "seed-guide" insert made of gold alloy. This new insert has cutouts which match the seed pattern of the Silastic carrier, but allows the seeds to be glued directly to the inner surface of the gold backing using either dental acrylic or a cyanoacrylate adhesive. When glued directly to the gold backing the seeds are offset a few tenths of a millimeter further away from the scleral surface compared to using the Silastic carrier. From a dosimetric perspective, the space formerly occupied by the Silastic carrier is now assumed to be water equivalent. Water equivalency is a desirable attribute for this space because it eliminates the dosimetric uncertainties related to the atomic composition of Silastic and thereby facilitates the use of either 125I and/or 103Pd seeds. The caveat is that a new source of dosimetric uncertainty would be introduced were an air bubble to become trapped in this space during or after the surgical insertion. The presence of air in this space is modeled and the dosimetric impact discussed. Another unintended consequence of water equivalency is that some fluorescent x rays emitted from the gold backing can now reach the eye. These very low energy x rays were virtually eliminated by absorption in Silastic. When loaded with 125I seeds the modified plaque appears to produce dose distributions that are almost the same as those of the original COMS plaque and the maximum dosimetric uncertainty introduced by an air bubble is about 2%. Dose distributions calculated for a modified plaque loaded with 103Pd seeds show that dose to healthy ocular structures distal to the tumor apex can be reduced compared to 125I. Clearly, it is faster and easier to glue seeds into the reusable gold seed-guide insert than it is to load the COMS-Silastic carrier.
Collapse
Affiliation(s)
- Melvin A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles, California 90033, USA.
| | | | | |
Collapse
|
11
|
Astrahan MA. Improved treatment planning for COMS eye plaques. Int J Radiat Oncol Biol Phys 2005; 61:1227-42. [PMID: 15752905 DOI: 10.1016/j.ijrobp.2004.09.062] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2004] [Revised: 09/28/2004] [Accepted: 09/30/2004] [Indexed: 11/30/2022]
Abstract
PURPOSE A recent reanalysis of the Collaborative Ocular Melanoma Study (COMS) medium tumor trial concluded that incorporating factors to account for anisotropy, line source approximation, the gold plaque, and attenuation in the Silastic seed carrier into the dose calculations resulted in a significant and consistent reduction of calculated doses to structures of interest within the eye. The authors concluded that future eye plaque dosimetry should be "performed using the most up-to-date parameters available." The reason these factors are important is attributable to the low energy (125)I radiation (approximately 28 keV) that is primarily absorbed by the photoelectric process. Photoelectric absorption is quite dependent on the atomic composition of the absorbing material. Being 40% silicon by weight, the effective atomic number of Silastic is significantly greater than that of water. Although the AAPM TG43 brachytherapy formalism inherently addresses the issues of source anisotropy and geometry, its parameter that accounts for scatter and attenuation, the radial dose function g(r), assumes that the source is immersed in infinite homogeneous water. In this work, factors are proposed for (125)I that correct for attenuation in the Silastic carrier and scatter deficits resulting from the gold plaque and nearby air. The implications of using (103)Pd seeds in COMS plaques are also discussed. METHODS AND MATERIALS An existing TG43-based ophthalmic plaque planning system was modified to incorporate additional scatter and attenuation correction factors that better account for the path length of primary radiation in the Silastic seed carrier and the distance between the dose calculation point and the eye-air interface. RESULTS Compared with homogeneous water, the dose-modifying effects of the Silastic and gold are greatest near the plaque surface and immediately adjacent to the plaque, while being least near the center of the eye. The calculated dose distribution surrounding a single (125)I seed centered in a COMS 20 mm plaque was found to be consistent with previously published examples that used thermoluminescent dosimetry measurements and Monte Carlo methods. For fully loaded 12 and 20 mm plaques, calculated dose to critical ocular structures ranged from 16%-50% less than would have been reported using the standard COMS dose calculation protocol. CONCLUSIONS Treatment planning for COMS eye plaques that accurately accounts for the presence of the gold, Silastic and extraocular air is both possible and practical.
Collapse
Affiliation(s)
- Melvin A Astrahan
- Department of Radiation Oncology, University of Southern California Norris Cancer Hospital, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA.
| |
Collapse
|
12
|
Granero D, Pérez-Calatayud J, Ballester F, Casal E, de Frutos JM. Dosimetric study of the 15mm ROPES eye plaque. Med Phys 2004; 31:3330-6. [PMID: 15651616 DOI: 10.1118/1.1812605] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
The main aim of this paper is to make a study of dose-rate distributions obtained around the 15 mm, radiation oncology physics and engineering services, Australia (ROPES) eye plaque loaded with 125I model 6711 radioactive seeds. In this study, we have carried out a comparison of the dose-rate distributions obtained by the algorithm used by the Plaque Simulator (PS) (BEBIG GmbH, Berlin, Germany) treatment planning system with those obtained by means of the Monte Carlo method for the ROPES eye plaque. A simple method to obtain the dose-rate distributions in a treatment planning system via the superposition of the dose-rate distributions of a seed placed in the eye plaque has been developed. The method uses eye plaque located in a simplified geometry of the head anatomy and distributions obtained by means of the Monte Carlo code GEANT4. The favorable results obtained in the development of this method suggest that it could be implemented on a treatment planning system to improve dose-rate calculations. We have also found that the dose-rate falls sharply along the eye and that outside the eye the dose-rate is very low. Furthermore, the lack of backscatter photons from the air located outside the eye-head phantom produces a dose reduction negligible for distances from the eye-plaque r<1 cm but reaches up to 20% near the air-eye interface. Results showed that the treatment planning system lacks accuracy around the border of the eye (in the sclera and the surrounding area) due to the simplicity of the algorithm used. The BEBIG treatment planning system uses a global attenuation factor that takes into account the effect of the eye plaque seed carrier and the lack of backscatter photons caused by the metallic cover, which in the case of a ROPES eye plaque has a default value of T= 1 (no correction). In the present study, a global attenuation factor T=0.96 and an air-interface correction factor which improve on treatment planning system calculations were obtained.
Collapse
Affiliation(s)
- D Granero
- Department of Atomic, Molecular and Nuclear Physics and IFIC, University of Valencia-CSIC, Dr Moliner 50, E46100 Burjassot, Spain
| | | | | | | | | |
Collapse
|
13
|
Krintz AL, Hanson WF, Ibbott GS, Followill DS. A reanalysis of the Collaborative Ocular Melanoma Study Medium Tumor Trial eye plaque dosimetry. Int J Radiat Oncol Biol Phys 2003; 56:889-98. [PMID: 12788199 DOI: 10.1016/s0360-3016(03)00211-6] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE To recalculate the radiation doses delivered to structures of interest within the eye, i.e., the lens, tumor apex, 5-mm point, optic disk, and macula for patients treated with eye plaque radiotherapy on the Collaborative Ocular Melanoma Study (COMS) Medium Tumor Trial, using updated dosimetric data. METHODS AND MATERIALS Using the Plaque Simulator planning system, doses were recalculated for a sampling of COMS patients for each plaque size. Dosimetry parameters incorporated into the recalculation were line source approximation, a 90% Silastic transmission factor, and a 0% gold transmission factor. Generic solutions were generated from the dose recalculations for each plaque size and structures of interest combination. Doses for the remainder of the patient population were recalculated using the generic solutions and compared with the originally reported COMS doses. RESULTS Doses to all structures of interest were reduced 7%-21%, depending on the plaque size and structure combination. The reduction in dose for the macula, optic disc, lens, tumor apex, and 5-mm point was on average 10%, 18%, 8%, 11%, and 12%, respectively. The closer the macula and optic disk were to the plaque rim, the greater the dose reduction. Incorporation of the Silastic transmission factor accounted for a large part of the dose reduction. CONCLUSIONS Incorporating anisotropy, line source approximation, and Silastic and gold shield attenuation into dose recalculations resulted in a significant and consistent reduction of doses to structures of interest within the eyes.
Collapse
Affiliation(s)
- Amanda L Krintz
- Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | |
Collapse
|
14
|
Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 2003; 56:544-55. [PMID: 12738332 DOI: 10.1016/s0360-3016(03)00006-3] [Citation(s) in RCA: 167] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE This article presents the American Brachytherapy Society (ABS) guidelines for the use of brachytherapy for patients with choroidal melanomas. METHODS Members of the ABS with expertise in choroidal melanoma formulated brachytherapy guidelines based upon their clinical experience and a review of the literature. The Board of Directors of the ABS approved the final report. RESULTS Episcleral plaque brachytherapy is a complex procedure and should only be undertaken in specialized medical centers with expertise in this sophisticated treatment program. Recommendations were made for patient selection, techniques, dose rates, and dosages. Most patients with very small uveal melanomas (<2.5 mm height and <10 mm in largest basal dimension) should be observed for tumor growth before treatment. Patients with a clinical diagnosis of medium-sized choroidal melanoma (between 2.5 and 10 mm in height and <16 mm basal diameter) are candidates for episcleral plaques if the patient is otherwise healthy and without metastatic disease. A histopathologic verification is not required. Small melanomas may be candidates if there is documented growth; some patients with large melanomas (>10 mm height or >16 mm basal diameter) may also be candidates. Patients with large tumors or with tumors at peripapillary and macular locations have a poorer visual outcome and lower local control that must be taken into account in the patient decision-making process. Patients with gross extrascleral extension, ring melanoma, and tumor involvement of more than half of the ciliary body are not suitable for plaque therapy. For plaque fabrication, the ophthalmologist must provide the tumor size (including basal diameters and tumor height) and a detailed fundus diagram. The ABS recommends a minimum tumor (125)I dose of 85 Gy at a dose rate of 0.60-1.05 Gy/h using AAPM TG-43 formalism for the calculation of dose. NRC or state licensing guidelines regarding procedures for handling of radioisotopes must be followed. CONCLUSIONS Brachytherapy represents an effective means of treating patients with choroidal melanomas. Guidelines are established for the use of brachytherapy in the treatment of choroidal melanomas. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their treatment and dose reporting policies. These guidelines will be modified as further clinical results become available.
Collapse
Affiliation(s)
- Subir Nag
- Department of Radiation Oncology, Ohio State University, Columbus, OH 43210, USA.
| | | | | | | | | | | |
Collapse
|
15
|
Yu C, Luxton G. TLD dose measurement: a simplified accurate technique for the dose range from 0.5 cGy to 1000 cGy. Med Phys 1999; 26:1010-6. [PMID: 10436903 DOI: 10.1118/1.598493] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
A simplified TLD technique characterized by high precision and reproducibility of dose measurement is presented. One hundred eighty LiF TLD rods 1 mm diam x 3 mm length as obtained from the manufacturer were annealed for 1 h at 400 degrees C followed immediately by 2 h at 105 degrees C. After exposure to a dose of 1 Gy of 4 MV x rays, TLDs were annealed for 15 min at 105 degrees C, then read out. TLDs were then sorted into five groups, ranging from 26 to 50 rods each with approximately equal sensitivity after correcting for the drift in the sensitivity of the TLD reader during the readout session. Maintaining group identity, the TLDs were again annealed, irradiated and read out. Fewer than 10% of the TLDs were removed from each group because the corrected readings differed from the respective group mean by more than 3.5%. The standard deviation of the readout was approximately 1.5% within each group. The planchet heater was not flushed with nitrogen gas. Various tests were performed to assess the stability of the group sorting technique and the linearity of TLD dose response. After reannealing, five TLDs were randomly drawn from one of the presorted groups, and subjected to various dose of 4 MV radiation over the range from 0.5 to 1000 cGy. This resulted in an average readout standard deviation of 1.2%. Response per unit dose was almost flat over the range from 0.5 cGy to 100 cGy, and increased by 15% over the range from 100 cGy to 1000 cGy. TLD sensitivity was affected by the duration of the anneal, but was virtually independent of the various time delays between irradiation, prereadout anneal, and readout. The group annealing and sorting (GAS) procedure provides a simple, reliable, precise, convenient, and accurate method for TLD measurements.
Collapse
Affiliation(s)
- C Yu
- Department of Radiation Oncology, University of Southern California, School of Medicine, Los Angeles 90033, USA
| | | |
Collapse
|
16
|
Finger PT, Berson A, Ng T, Szechter A. Ophthalmic plaque radiotherapy for age-related macular degeneration associated with subretinal neovascularization. Am J Ophthalmol 1999; 127:170-7. [PMID: 10030559 DOI: 10.1016/s0002-9394(98)00389-4] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
PURPOSE To evaluate ophthalmic plaque radiotherapy for the treatment of subretinal neovascularization associated with age-related macular degeneration. METHODS In a prospective phase I clinical trial, we treated 23 patients (23 eyes) with ophthalmic plaque radiotherapy for subfoveal exudative macular degeneration. Palladium 103 ophthalmic plaque brachytherapy was delivered to a retinal apex dose of 1,250 to 2,362 cGy (rad). Early Treatment Diabetic Retinopathy Study type visual acuity determinations, ophthalmic examinations, and angiography were performed before and after treatment. Clinical evaluations were performed in a nonrandomized and unmasked fashion. RESULTS Patients were followed up for a mean (+/-SD) of 19 +/- 10.7 months (range, 3 to 37 months). Six months after radiation therapy, three (16%) of 19 eyes had lost 3 or more lines of best-corrected visual acuity; 12 months after radiation therapy, four eyes (31% of 13 eyes), and 24 months after radiation therapy, only two (22% of nine eyes) lost 3 or more lines of visual acuity. No eye suffered sudden irreversible loss of central vision. No radiation retinopathy, optic neuropathy, or cataract could be attributed to radiotherapy within this follow-up period. CONCLUSION Ophthalmic plaque radiotherapy can be used to treat neovascular age-related macular degeneration. In contrast to external beam radiotherapy, ophthalmic plaque radiotherapy is a unilateral treatment, which allows a larger dose to be delivered to the macula with less irradiation of normal ocular structures. We have found no sight-limiting complications at the doses, dose rates, and follow-up evaluated in this study.
Collapse
Affiliation(s)
- P T Finger
- Department of Ophthalmology, New York Eye and Ear Infirmary, New York 10003, USA.
| | | | | | | |
Collapse
|
17
|
Abstract
PURPOSE Episcleral plaque therapy (EPT) with sealed 125I sources is widely used in the treatment of choroidal melanoma. In EPT, as elsewhere in radiotherapy, concern for normal tissue tolerance has frequently been a dose-limiting factor. The concept of conformal therapy, which seeks to improve dose homogeneity within the tumor and greatly reduce the dose to uninvolved structures may provide a solution to this problem. Radioactive sources are typically distributed uniformly over the surface of an episcleral plaque and are sometimes offset slightly from the scleral surface to reduce the dose to the sclera relative to the apex and prescribed therapeutic margin at the tumor base. Nevertheless, it is not uncommon for scleral dose to exceed the dose to the apex of intermediate to tall tumors by a factor of 4 or more. The availability of low-energy sealed sources such as 125I prompted the development of gold-backed plaques to shield noninvolved periocular tissues. The concept of shielding can be extended to include collimation of individual sources. The potential advantages of individual source collimation include reduced scleral dose, more homogeneous tumor dose, and superior shielding of adjacent normal structures such as the fovea as compared to previous plaque designs. METHODS AND MATERIALS A three-dimensional treatment-planning system has been extended to design a plaque that incorporates individually collimated 125I sources. Thermoluminescent dosimetry (TLD) and radiochromic film were used to compare calculated dose-rate distributions with measured dose rates in an acrylic phantom. RESULTS Calculations predict that source collimation in the form of a "slotted" gold plaque will achieve the purposes of the study. The collimating effect of the slots is demonstrated qualitatively using radiochromic film, and the accuracy of the calculation is demonstrated quantitatively with TLD. CONCLUSION The episcleral plaque described in this report is simpler to assemble than previous plaque designs. It produces a more homogeneous dose distribution in the tumor, reduces scleral dose by up to 50% as compared to conventional designs, and significantly reduces radiation dose to uninvolved structures adjacent to the plaque.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033, USA
| | | | | | | |
Collapse
|
18
|
Finger PT, Berson A, Sherr D, Riley R, Balkin RA, Bosworth JL. Radiation therapy for subretinal neovascularization. Ophthalmology 1996; 103:878-89. [PMID: 8643242 DOI: 10.1016/s0161-6420(96)30592-7] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
PURPOSE To evaluate low-dose external beam irradiation and plaque radiotherapy for the treatment of subretinal neovascularization. METHODS The authors treated 137 patients with radiation therapy for subretinal neovascularization. Herein, they examine a subset of 75 patients with exudative age-related macular degeneration who were treated with (4- or 6-MV photons) external beam irradiation at a dose of 1200 to 1500 cGy to the affected macula. In addition, six patients were treated with palladium 103 ophthalmic plaque brachytherapy to an equivalent retinal apex dose of 1200 to 1500 cGy. The authors compared the intralesional, intraocular, and intracranial radiation dose distributions of each treatment modality. Early Treatment Diabetic Retinopathy Study-type visual acuity determinations, ophthalmic examinations, and angiography were performed before and after treatment. Clinical evaluations were performed in a nonrandomized and unmasked fashion. RESULTS Episcleral plaque brachytherapy was found to provide a higher average radiation dose within the neovascular tissues while delivering less radiation to most normal ocular (both eyes) and all intracranial structures. Both forms of radiotherapy were associated with decreased hemorrhages, exudates, and leakage of neovascular membranes. Ten (13 percent) patients receiving external beam radiotherapy had transient epiphora and ocular irritation. CONCLUSION Observation and laser photocoagulation of subfoveal neovascularization have been associated with poor visual outcomes. Pilot experience suggests that low-dose radiotherapy offers a method to treat subretinal neovascularization without destroying the overlying retina. Although the authors' radiation distribution studies favored plaque radiotherapy, additional factors such as relative efficacy, expense, convenience, and safety must be investigated.
Collapse
Affiliation(s)
- P T Finger
- Department of Ophthalmology, The New York Eye and Ear Infirmary, New York, USA
| | | | | | | | | | | |
Collapse
|
19
|
Finger PT, Buffa A, Mishra S, Berson A, Bosworth JL, Vikram B. Palladium 103 plaque radiotherapy for uveal melanoma. Clinical experience. Ophthalmology 1994; 101:256-63. [PMID: 8115147 DOI: 10.1016/s0161-6420(94)31338-8] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
PURPOSE To evaluate the effect of palladium 103(103Pd) ophthalmic plaque brachytherapy on patients with uveal melanoma. BACKGROUND Radioactive 103Pd seeds have become available for plaque brachytherapy, and computer-aided simulations have compared the intraocular dose distribution of 103Pd versus iodine 125 (125I) plaques in patients with uveal melanoma. The use of the lower-energy radionuclide 103Pd increased the radiation to the tumors and decreases irradiation of most normal ocular structures. METHODS The authors have begun a phase 1 clinical trial evaluating the effect of 103Pd ophthalmic plaque radiotherapy on intraocular tumors. Uveal melanoma was diagnosed, and the patients were found to be negative for metastatic disease. All patients were given one 103Pd radioactive plaque treatment, and six patients also were given adjuvant microwave hyperthermia. RESULTS Palladium 103 ophthalmic plaque radiotherapy was used to treat 23 patients with uveal melanoma. Patients were followed for up to 27 months (mean, 13.5 months). One eye was enucleated for progressive tumor enlargement (4 months after treatment). One patient died (of metastatic melanoma). Eight patients have lost greater than two lines of visual acuity, one has gained more than two lines. Fifteen patients (65%) were within two lines or had better than their preoperative visual acuity. Relating to the effect of treatment on visual acuity, 15 (65%) tumors were located equal to or less than 2 mm from the fovea. CONCLUSION Palladium 103 ophthalmic plaque radiotherapy was noted to control the growth of uveal melanomas. Compared with other forms of plaque radiotherapy at this follow-up interval, the authors have noted no new complications, no difference in local control, and/or changes in tumor response to treatment. More long-term follow-up will be required to demonstrate differences between 125I and 103Pd ophthalmic plaque brachytherapy.
Collapse
Affiliation(s)
- P T Finger
- Department of Ophthalmology, New York Eye and Ear Infirmary, New York 10003
| | | | | | | | | | | |
Collapse
|
20
|
Finger PT, Lu D, Buffa A, DeBlasio DS, Bosworth JL. Palladium-103 versus iodine-125 for ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys 1993; 27:849-54. [PMID: 8244814 DOI: 10.1016/0360-3016(93)90459-9] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
PURPOSE A dosimetry study comparing the use of I-125 vs. Pd-103 radioactive seeds for ophthalmic plaque brachytherapy. METHODS AND MATERIALS Palladium-103 (Pd-103) seeds in ophthalmic plaques were used to treat 15 patients with intraocular malignant melanoma. Computer-aided simulations were performed to evaluate the intraocular dose distribution of I-125 versus Pd-103 ophthalmic plaques (delivering equivalent apex doses). Seven target points were selected. Starting at the outer scleral surface, four were located along the central axis of the plaque: the 1 mm point (the inner sclera), the 6 mm point, the tumors apex, and the opposite eye wall. We also evaluated the fovea, optic nerve, and the lens because they were considered to be critical structures. RESULTS These studies demonstrated that the lower energy photons generated by Pd-103 seeds (average 21 KeV) in ophthalmic plaques were more rapidly absorbed in tissue than photons generated by I-125 (average 28 KeV). Therefore, during ophthalmic plaque radiotherapy, Pd-103 photons were found to be more rapidly absorbed within the tumor and less likely to reach most normal ocular structures. On average, the use of Pd-103 decreased the dose to the fovea by 5.7%, to the optic nerve by 8.4%, to the lens by 26%, and to the opposite eye wall by 38.4%. CONCLUSION Palladium-103 ophthalmic plaque brachytherapy resulted in slightly more irradiation of the tumor and less radiation to most normal ocular structures.
Collapse
Affiliation(s)
- P T Finger
- Department of Ophthalmology, North Shore University Hospital-Cornell University Medical College, Manhasset, NY 11030
| | | | | | | | | |
Collapse
|
21
|
Hermann KP, Alberti W, Tabor P, Pothmann B, Divoux S, Harder D. Solid phantom material for the dosimetry of iodine-125 seed ophthalmic plaques. Int J Radiat Oncol Biol Phys 1993; 26:897-901. [PMID: 8344860 DOI: 10.1016/0360-3016(93)90507-r] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
PURPOSE A tissue-equivalent solid phantom material, RE-1, closely simulating the radiological attenuation and scattering properties of the human eye for the iodine-125 photon spectrum and their Compton-scattered secondary photons, was fabricated on a polyethylene base with CaCO3 and MgO as inorganic additives. METHODS AND MATERIALS A 24 mm diameter spherical phantom was made from 1.1 mm thick sheets of RE-1, and holes were drilled in which 1 mm3 TLD cubes were placed. RESULTS The radial dose function g(r), which determines the dose profile on the transverse axis, was measured in a quasi-infinite phantom of RE-1. CONCLUSION The values obtained deviate only slightly from those for a quasi-infinite phantom made from water-equivalent material.
Collapse
Affiliation(s)
- K P Hermann
- Institut für Medizinische Physik und Biophysik, Universität Göttingen, Germany
| | | | | | | | | | | |
Collapse
|
22
|
Alberti W, Divoux S, Pothmann B, Tabor P, Hermann KP, Harder D. Autoradiography for iodine-125 seeds. Int J Radiat Oncol Biol Phys 1993; 25:881-4. [PMID: 8478240 DOI: 10.1016/0360-3016(93)90319-q] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
To study the interior design of model 6702 and 6711 iodine-125 seeds contact autoradiographs were performed using mammography film. Improved resolution was obtained using a pin-hole camera with a hole of 0.1 mm x 0.1 mm. With these techniques, qualitative determination of the relative activity distribution within each seed was possible. The number of the activated resin spheres and the positions of the centers of these spheres can be exactly determined. A model calculation shows, that variations in the arrangement of the activated spheres within a seed have a moderate influence on the dose distribution at source distances below 10 mm. Knowing the exact source configuration may be useful when comparing dose calculations with measured data for model 6702 125I seeds which are currently employed in ophthalmic plaque and implant therapy of other tumors.
Collapse
Affiliation(s)
- W Alberti
- Klinik für Strahlentherapie und Nuklearmedizin, Alfried Krupp Krankenhaus, Essen, Germany
| | | | | | | | | | | |
Collapse
|
23
|
|
24
|
Abstract
Standardized radioactive plaques have been used in the irradiation of intraocular tumors. These plaques have defined slots to accommodate 125I seeds and hence produce predictable isodose distributions. The seed strength has to be adjusted to deliver 100 Gy to the prescription point, which varies with the tumor size. The purpose of this work is to develop lookup tables that relate the seed strength to different prescription distances. Dose rates were determined for a set of standardized eye plaques. Using these dose rates and the source strength decaying expression, the seed strengths were determined as a function of distance along a line through the plaque. Two seed-strength tables were created based on four-day and five-day treatment times delivering a 100 Gy to the prescription distance.
Collapse
Affiliation(s)
- C B Saw
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, PA 15213
| | | | | | | | | |
Collapse
|
25
|
Abstract
Microwave thermoradiotherapy was used as a primary treatment for 44 patients with choroidal melanoma. An episcleral dish-shaped microwave antenna was placed beneath the tumour at the time of plaque brachytherapy. While temperatures were measured at the sclera, the tumour's apex was targeted to receive a minimum of 42 degrees C for 45 minutes. In addition, the patients received full or reduced doses of plaque radiotherapy. No patients have been lost to follow-up. Two eyes have been enucleated: one for rubeotic glaucoma, and one for uveitic glaucoma. Though six patients have died, only one death was due to metastatic choroidal melanoma (39 months after treatment). Clinical observations suggest that the addition of microwave heating to plaque radiation therapy of choroidal melanoma has been well tolerated. There has been a 97.7% local control rate (with a mean follow-up of 22.2 months). We have reduced the minimum tumour radiation dose (apex dose) to levels used for thermoradiotherapy of cutaneous melanomas (50 Gy/5000 rad). Within the range of this follow-up period no adverse effects which might preclude the use of this microwave heat delivery system for treatment of choroidal melanoma have been noted.
Collapse
Affiliation(s)
- P T Finger
- Department of Ophthalmology, North Shore University Hospital-Cornell University Medical College, Manhasset, New York 11030
| |
Collapse
|
26
|
Alberti W, Pothmann B, Tabor P, Muskalla K, Hermann KP, Harder D. Dosimetry and physical treatment planning for iodine eye plaque therapy. Int J Radiat Oncol Biol Phys 1991; 20:1087-92. [PMID: 2022510 DOI: 10.1016/0360-3016(91)90209-m] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The dosimetry of eye plaques loaded with iodine-125 seeds (type 6702) was performed by means of computer calculations and measurements with thermoluminescent dosimeters (TLD). Measurements of the depth dose distribution (2-25.5 mm) along the transverse axis of a single seed were performed in water equivalent phantom material. The transverse axis attenuation and geometry factor F(r) was obtained by applying a least squares fit to the measured data. Based on the resulting radial dose function, a computer program was developed which calculates dose distributions within the eye for arbitrary loading and placement of the eye plaque. The computational results were verified by TLD measurements in an eye phantom.
Collapse
Affiliation(s)
- W Alberti
- Klinik für Strahlentherapie und Nuklearmedizin, Alfried Krupp Krankenhaus, Essen, FRG
| | | | | | | | | | | |
Collapse
|
27
|
Karolis C, Frost RB, Billson FA. A thin I-125 seed eye plaque to treat intraocular tumors using an acrylic insert to precisely position the sources. Int J Radiat Oncol Biol Phys 1990; 18:1209-13. [PMID: 2347728 DOI: 10.1016/0360-3016(90)90459-w] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A thin re-usable stainless steel ophthalmic applicator is described. The radioactive Iodine-125 sources are inserted in an acrylic button which fits neatly into a stainless steel shell 1 mm thick. The applicator can be assembled with the radioactive sources precisely positioned without the use of adhesives or mechanical devices such as clamps or screws in a matter of a few minutes, (under sterile conditions if necessary). The applicator can be dismantled in seconds after which it is ready for cleaning and re-sterilization. The overall thickness of the plaque is 2.6 mm, but this has the potential to be reduced to 2.1 mm. Suture holes are provided on a flange subtending 120 degrees around the circumference of the shell and are exactly matched on a stainless steel template.
Collapse
Affiliation(s)
- C Karolis
- Department of Medical Physics, Prince of Wales Hospital, Sydney, N.S.W., Australia
| | | | | |
Collapse
|
28
|
Luxton G, Astrahan MA, Findley DO, Petrovich Z. Measurement of dose rate from exposure-calibrated 125I seeds. Int J Radiat Oncol Biol Phys 1990; 18:1199-207. [PMID: 2347727 DOI: 10.1016/0360-3016(90)90458-v] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Dose rate in water 1 cm transverse to an 125I seed calibrated for air kerma strength is not well established; 125I dosimetry calculations are, however, based on this constant. The specific dose constant was obtained from a series of dose rate measurements using thermoluminescent dosimetry (TLD) in a rigid geometry, full scatter acrylic phantom for individual model 6711 seeds. With a statistical precision of approximately +/- .5%, the dose rate to an infinitesimal mass of water located in acrylic at a perpendicular distance of 1 cm from the seed was found to be 0.977 cGy/h per microGy-m2/h of air kerma strength. Dose rate in a water phantom was calculated using a model that takes into account differences in both attenuation and scatter between water and acrylic. The specific dose constant in water was determined to be 0.932 (1.184 cGy-cm2/mCi-h, for the conventional exposure rate constant of 1.45 R cm2/mCi-h). This value is 7.5% less than dose rate in water from an unattenuated point source, and 9.7% less than the value commonly used for dosimetry calculations. The results suggest that most clinical 125I dosimetry estimates to date should be reconsidered for a possible reduction by about 10%. Relative scatter attenuation factors at 3 and 5 mm are also presented.
Collapse
Affiliation(s)
- G Luxton
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | | | |
Collapse
|
29
|
Astrahan MA, Luxton G, Jozsef G, Kampp TD, Liggett PE, Sapozink MD, Petrovich Z. An interactive treatment planning system for ophthalmic plaque radiotherapy. Int J Radiat Oncol Biol Phys 1990; 18:679-87. [PMID: 2318702 DOI: 10.1016/0360-3016(90)90077-w] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Brachytherapy using removable episcleral plaques containing sealed radioisotope sources is being studied as an alternative to enucleation in the treatment of choroidal melanoma and other tumors of the eye. Encouraging early results have been reported, but late complications which lead to loss of vision continue to be a problem. A randomized national study, the Collaborative Ocular Melanoma Study (COMS) is currently in progress to evaluate the procedure. The COMS specified isotope is 125I. Precise dosimetric calculations near the plaque may correlate strongly with complications and could also be used to optimize isotope loading patterns in the plaques. A microcomputer based treatment planning system has been developed for ophthalmic plaque brachytherapy. The program incorporates an interactive, 3-dimensional, solid-surface, color-graphic interface. The program currently supports 125I and 192Ir seeds which are treated as anisotropic line sources. Collimation effects related to plaque structure are accounted for, permitting detailed study of shielding effectiveness near the lip of a plaque. A dose distribution matrix may be calculated in any subregion of a transverse, sagittal, or coronal planar cross section of the eye, in any plane transecting the plaque and crossing the eye diametrically, or on a spherical surface within or surrounding the eye. Spherical surfaces may be displayed as 3-dimensional perspective projections or as funduscopic diagrams. Isodose contours are interpolated from the dose matrix. A pointer is also available to explicitly calculate and display dose at any location on the dosimetry surface. An interactive editing capability allows new plaque designs to be rapidly added to the system.
Collapse
Affiliation(s)
- M A Astrahan
- Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033
| | | | | | | | | | | | | |
Collapse
|